Ensysce Biosciences, Inc. (ENSC) Stock Price & Analysis
Ensysce Biosciences, Inc. (ENSC) rose 3.57% to USD 0.46 as of September 8, 2026 at 06:22 UTC, according to Nexqual real-time market data.
ENSC last closed at USD 0.46; the session ranged USD 0.41–0.46 on volume of 550,361 shares. Market capitalization is —, with a 52-week range of USD 0.23–2.75 (NCM). Source: Nexqual, September 8, 2026 at 06:22 UTC.
Key Statistics (as of September 8, 2026 at 06:22 UTC)
| Price | USD 0.46 |
|---|---|
| Change | ▲ 3.57% (up) |
| Previous Close | USD 0.46 |
| Open | USD 0.46 |
| Day Range | USD 0.41 – 0.46 |
| 52-Week Range | USD 0.23 – 2.75 |
| Volume | 550,361 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ENSC)
Nexqual's technical model rates ENSC "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 06:22 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.39 (neutral) |
| vs SMA50 | Above (USD 0.34) |
| MACD | 0.02 (positive) |
From Ensysce Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Prescription opioid abuse presents major burdens to society, resulting in significant costs, illnesses, and deaths, many of which we believe could be prevented through the use of our proprietary technologies.
- We seek to protect our proprietary information, in part, using confidentiality and invention assignment agreements with our commercial partners, collaborators, employees, and consultants.
- These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with an employee or a third party.
Partnerships
- We also rely on trademarks, trade secrets, know-how, continuing technological innovation, and potential in-licensing opportunities to develop and maintain our proprietary position.   In August 2020, EBIR entered into a Technology Transfer Agreement with Mucokinetica to acquire its intellectual property and all assets associated with the inhaled nafamostat program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRI | Biofrontera Inc. | USD 1.61 | ▲ 5.92% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 7.26 | ▲ 7.72% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▲ 0% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 20% |
| PALI | Palisade Bio, Inc. | USD 2.09 | ▲ 5.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:22 UTC. This page is informational and not investment advice.